Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 3/20 | 0.36 |
| ▸ | CDK8 | P49336 | 3/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881638 | 0.89 | AR (0.42) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL3887872 | 0.88 | AR (0.41) | ARTRPA1CCNCCDK8CREBBP | |
| Ak-106 SCHEMBL924434 | 0.88 | AR (0.43) | ARTRPA1CCNCCDK8CREBBP | |
| Ak-106 SCHEMBL29359236 | 0.88 | AR (0.43) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL924797 | 0.87 | AR (0.44) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL2944409 | 0.85 | AR (0.39) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL2944414 | 0.85 | AR (0.39) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL3884516 | 0.85 | FFAR4 (0.43) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL925771 | 0.81 | AR (0.39) | ARTRPA1CCNCCDK8CREBBP | |
| SCHEMBL925678 | 0.81 | USP7 (0.40) | ARCCNCCDK8CREBBPPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | AR 630/4885TRPA1 135/4885CCNC 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.